Suraksha Diagnostic has released the audio recording of its earnings call held on August 13, 2026, at 11:30 am. The session addressed the company's unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as well as broader business discussions.

The recording is accessible via the company's official website, fulfilling regulatory disclosure requirements under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30(6) and Regulation 46(2) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. These regulations mandate timely disclosure of material information to stock exchanges to ensure equal access to investors.

Ritu Mittal, Joint Managing Director & CEO, signed the communication. The filing was directed to the secretaries of both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).

Key Details

• Event: Earnings Call Audio Recording Release
• Date of Call: August 13, 2026
• Time: 11:30 am
• Financial Period Covered: Quarter ended June 30, 2026 (Q4FY26)
• Results Type: Unaudited Standalone and Consolidated
• Signatory: Ritu Mittal (Joint Managing Director & CEO)

The release ensures that institutional investors, analysts, and retail shareholders have access to the management's commentary on the financial performance for the full fiscal year 2026 and the final quarter.

Suraksha Diagnostic Limited reported a strong turnaround in profitability for the first quarter of FY27, posting a consolidated net profit of ₹18.62 crore compared to a net loss of ₹7.16 crore in the same period of FY26. The healthcare diagnostics firm also saw its total income rise by over 10% year-on-year to ₹441.96 crore, driven by operational efficiency that more than doubled its EBITDA to ₹58.93 crore from ₹28.96 crore previously.

The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on August 12, 2026. The results have been subjected to a limited review by the company’s statutory auditors. Joint Managing Director and CEO Ritu Mittal signed off on the disclosure, which was filed with the BSE and NSE under Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Financial Performance

The company’s revenue growth was accompanied by a sharp improvement in operating margins. While total income increased moderately, the EBITDA expansion indicates better cost management or higher-margin mix in its diagnostic services. The tangible net worth also strengthened, rising to ₹880.22 crore as of June 30, 2026, from ₹807.13 crore a year ago.

What the Numbers Show

The divergence between revenue growth and profit expansion is notable. While top-line revenue grew by approximately 10%, the bottom line swung from a loss to a profit, with EBITDA more than doubling. This suggests that the primary driver for the improved profitability was not just volume growth but significant operational leverage or cost containment measures implemented during the quarter. The absence of exceptional items or large other-income contributions in the provided extract implies this was an operational turnaround.

The full format of the financial results is available on the stock exchange websites and the company’s official portal.